# Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata

> clinical trial · VERIFIED · 2026-06-22

Status: RECRUITING · Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) · Condition: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)

- Company: National Institute of Allergy and Infectious Diseases (NIAID)
- Sector: immunology
- Primary source: https://clinicaltrials.gov/study/NCT05398809

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.